# US 2019/0169124 A1 · New derivatives of indole for the treatment of cancer, viral infections and lung diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0169124 A1 - Document ID: US20190169124A1 - Status: Published application - Kind: A1 - Application number: 16/257,096 - Filed: 2019-01-25 - Published: 2019-06-06 - Earliest claimed: 2012-12-07 - Assignees: Biokinesis; Centre National De La Recherche Scientifique - Applicants: Biokinesis; Centre National De La Recherche Scientifique - Inventors: CECILE BOUGERET; CATHERINE GUILLOU; JULIEN ROULEAU; JULIE RIVOLLIER; DENIS CARNIATO - Web page: https://patentgrep.com/patent/US20190169124A1 ## CPC - C07D 209/18: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals - A61K 31/404: Indoles, e.g. pindolol - A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) - A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone - A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin - A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate - A61K 31/683: Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols - A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 9/12: Antihypertensives - A61P 11/00: Drugs for disorders of the respiratory system - A61P 31/12: Antivirals - A61P 31/18: for HIV - A61P 35/00: Antineoplastic agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C07C 211/63: having quaternised nitrogen atoms bound to acyclic carbon atoms - C07D 209/04: Indoles; Hydrogenated indoles - C07D 209/26: with an acyl radical attached to the ring nitrogen atom - C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms - C07D 401/14: containing three or more hetero rings - C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms - C07D 405/14: containing three or more hetero rings - C07F 9/09: Esters of phosphoric acids - C07F 9/40: Esters thereof - C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems} - C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS - C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22) ## Abstract The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases. ## Claims ### Claim 1 A method for treating a cancer in a subject in need thereof comprising administering an effective amount of a pharmaceutical composition comprising a compound of formula (I): wherein: X represents a nitrogen atom, a C—CN unit or a N+—O− unit; R1 and R1′ are such that one is H and the other represents a halogen or a (C1-C6)alkoxy group, optionally substituted by a carboxylic group or one —NR11R12 unit wherein R11 and R12 represent H, a (C1-C6)alkyl group, or R11 and R12 taken together form a 3- to 7-membered ring, optionally interrupted by one or several heteroatoms; R2 represents: a radical (C1-C6)alkoxy, (C3-C6)cycloalkoxy, aryloxy, heteroaryloxy, (C1-C6)alkyl-aryloxy, (C1-C6)alkyl-heteroaryloxy, said radicals being optionally substituted by at least one halogen, or a radical thio-(C1-C6)alkyl, thio-aryl, thio-heteroaryl, thio-(C1-C6)alkyl-aryl or thio-(C1-C6)-alkyl-heteroaryl, said radicals being optionally substituted by at least one halogen or by a (C1-C6)alkoxy group, a —NR4R5 unit, a O—(C1-C6)alkyl-NR4R5 unit or a S—(C1-C6)alkyl-NR4R5 unit wherein R4 and R5 represent H, a (C1-C6)alkyl group, or R4 and R5 taken together form a 3- to 7-membered ring, optionally interrupted by one or several heteroatoms, with the proviso that at least one among R4 and R5 is not H, a NHCOR6 unit wherein R6 represents (C1-C6)alkyl group, an aryl or heteroaryl group optionally substituted by at least one halogen, a trifluoromethyl group, or a (C1-C3)alkoxy group, or a halogen, with the proviso that if R1 or R1′ is a (C1-C3)alkoxy group, then R2 is not a halogen; and R3 represents a hydrogen, a (C1-C3)alkyl group, a (C1-C3)alkoxy group or a halogen, advantageously a fluorine; and the compounds of formula (I) as above defined, in which the nitrogen atom of the indole core is substituted by a group selected from the group consisting of a COR7 and a CO2R7 group, wherein R7 represents: a (C1-C6)alkyl group, optionally substituted by at least a hydroxy group, a (C1-C6)alkyloxy group, a (C1-C6)npolyalkyloxy group wherein n is 1